RESPONSE: Colorectal Cancer Survivors' Follow-up Care - Now Digital and Need-based

Launched by UNIVERSITY OF AARHUS · Sep 25, 2024

Keywords

ClinConnect Summary

The RESPONSE trial is studying a new follow-up care program for patients who have survived stage I and low-risk stage II colorectal cancer. This program aims to improve quality of life by addressing not only the fear of cancer coming back but also the psychological effects and any long-term side effects from treatment. Unlike the traditional follow-up care, which treats all patients the same, this new approach is tailored to each patient’s individual needs, using digital tools to monitor their health and provide support. Patients in the study will be compared to those receiving the usual follow-up care, to see if this new program helps them feel better overall.

To participate in this trial, you need to be at least 18 years old, have been treated for stage I or low-risk stage II colorectal cancer, and be able to use a smartphone app for support. The trial is currently looking for participants in Denmark. If you join, you can expect to receive personalized care that includes monitoring for any late effects of treatment, as well as tools to help manage your health and well-being. The researchers hope that this new program will help improve your quality of life without missing important cancer follow-up checks.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients treated for stage I and low risk stage II colorectal cancer with curative intend.
• • 2. Age 18 years or older.
• • 3. Understands spoken and written Danish language.
• • 4. Able to use digital care-guide as smartphone application.
• • 5. The patient is also included in DANISH.MRD part 1.
• Exclusion Criteria:
• • 1. Patients who are unlikely to comply with the protocol, unable to return for subsequent visits and/or otherwise considered by the PIs to be unlikely to complete the study.
• • 2. Patients who are not able or willing to adhere to the digital platform.
• • 3. Patients treated only with local endoscopic resection, e.g.,Transanal Endoscopic microsurgery (TEM).